Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression

Depression is a heterogenous and widespread disorder with a lifetime prevalence>20% (Hasin et al., 2018) that confers increased risk for medical illnesses which are known to be associated with inflammation, obesity and/or metabolic dysregulation including cardiovascular disease, diabetes, and cancer (Currier and Nemeroff, 2014; Musselman et al., 2003; Musselman et al., 1998). In this regard, 30-50% of patients with depression are reported to have high levels of inflammatory markers, including the acute phase reactant C-reactive protein (CRP), as well as high body mass index (BMI), and/or markers of metabolic dysregulation, all of which may predispose patients to the development of co-morbid medical illnesses (Felger et al., 2016; Rapaport et al., 2016; Rethorst et al., 2014; Shelton et al., 2015).

Source: Psychoneuroendocrinology - September 6, 2018 Category: Psychiatry Authors: Mandakh Bekhbat, Karen Chu, Ngoc-Anh Le, Bobbi J. Woolwine, Ebrahim Haroon, Andrew H. Miller, Jennifer C. Felger Source Type: research